{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T04:12:37Z","timestamp":1744517557456,"version":"3.40.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clinre.2025.102567","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T16:32:32Z","timestamp":1741019552000},"page":"102567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes in the presentation and characteristics OF HCV related hepatocellular carcinoma in the era of direct acting antiviral therapy: A retrospective study"],"prefix":"10.1016","volume":"49","author":[{"given":"Randa Salah","family":"Abdelmoneim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fathalla","family":"Sedki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3791-4781","authenticated-orcid":false,"given":"Mohamed Fathy","family":"Bakosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clinre.2025.102567_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"33","key":"10.1016\/j.clinre.2025.102567_bib0002","first-page":"5193","article-title":"Hepatocellular carcinoma in Egypt: a single center study over a decade","volume":"11","author":"El-Zayadi","year":"2005","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102567_bib0003","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12032-014-0432-7","article-title":"Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting","volume":"32","author":"Eltabbakh","year":"2015","journal-title":"Med Oncol"},{"issue":"7","key":"10.1016\/j.clinre.2025.102567_bib0004","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1080\/14787210.2020.1758065","article-title":"Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt","volume":"18","author":"Esmat","year":"2020","journal-title":"Expert Rev Anti-Infect Therapy"},{"issue":"4","key":"10.1016\/j.clinre.2025.102567_bib0005","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroentrology"},{"issue":"3","key":"10.1016\/j.clinre.2025.102567_bib0006","first-page":"227","article-title":"Korean liver cancer association-national cancer center Korea practice guidelines for the management of hepatocellular carcinoma","volume":"13","year":"2018","journal-title":"Gut Liver"},{"issue":"5","key":"10.1016\/j.clinre.2025.102567_bib0007","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroentrology"},{"issue":"1","key":"10.1016\/j.clinre.2025.102567_bib0008","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MEG.0000000000001264","article-title":"Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients","volume":"31","author":"Abdelaziz","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102567_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13027-020-00300-z","article-title":"Tumor aggression among hepatitis-C related hepatocellular carcinoma patients: an observational study regarding the impact of anti-HCV therapy","volume":"15","author":"Khalid","year":"2020","journal-title":"Infect Agent Cancer"},{"issue":"1\u20132","key":"10.1016\/j.clinre.2025.102567_bib0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000505326","article-title":"Changing patterns of hepatocellular carcinoma after treatment with direct antiviral agents","volume":"7","author":"El Fayoumie","year":"2020","journal-title":"Gastrointest Tumors"},{"issue":"4","key":"10.1016\/j.clinre.2025.102567_bib0011","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/gutjnl-2015-310033","article-title":"Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFN\u03b1","volume":"66","author":"Serti","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.clinre.2025.102567_bib0012","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2174\/1874357901812010016","article-title":"Vullo V. Hepatitis C virus and hepatocellular carcinoma: pathogenetic mechanisms and impact of direct-acting antivirals","volume":"12","author":"Schietroma","year":"2018","journal-title":"Open Virol J"},{"issue":"4","key":"10.1016\/j.clinre.2025.102567_bib0013","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2016.07.004","article-title":"Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution","volume":"65","author":"Nault","year":"2016","journal-title":"J Hepatol"},{"issue":"16","key":"10.1016\/j.clinre.2025.102567_bib0014","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3748\/wjg.v18.i16.1926","article-title":"Factors associated with the overall survival of elderly patients with hepatocellular carcinoma","volume":"18","author":"Fujii","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.clinre.2025.102567_bib0015","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102567_bib0016","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2025.102567_bib0017","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology (Baltim Md)"},{"issue":"1","key":"10.1016\/j.clinre.2025.102567_bib0018","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/hep.25950","article-title":"Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system","volume":"57","author":"Hsu","year":"2013","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinre.2025.102567_bib0019","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102567_bib0020","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2025.102567_bib0021","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12072-019-09939-2","article-title":"Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study","volume":"13","author":"Ide","year":"2019","journal-title":"Hepatol Int"},{"issue":"4","key":"10.1016\/j.clinre.2025.102567_bib0022","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000444394","article-title":"A hepatocellular carcinoma aggressiveness index and its relationship to liver enzyme levels","volume":"90","author":"Carr","year":"2016","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.clinre.2025.102567_bib0023","doi-asserted-by":"crossref","first-page":"187","DOI":"10.9745\/GHSP-D-20-00234","article-title":"Egypt's ambitious strategy to eliminate Hepatitis C virus: a case study","volume":"9","author":"Hassanin","year":"2021","journal-title":"Glob Health Sci Pract"},{"issue":"1","key":"10.1016\/j.clinre.2025.102567_bib0024","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/jvh.13408","article-title":"Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection","volume":"28","author":"Johnson","year":"2021","journal-title":"J Viral Hepat"},{"issue":"6","key":"10.1016\/j.clinre.2025.102567_bib0025","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.jhep.2020.08.006","article-title":"Hepatic benefits of HCV cure","volume":"73","author":"Calvaruso","year":"2020","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102567_bib0026","doi-asserted-by":"crossref","first-page":"597","DOI":"10.31557\/APJCP.2023.24.2.597","article-title":"Prospective comparison of hepatocellular carcinoma behavior and survival of patients who did or did not receive HCV direct-acting antivirals","volume":"24","author":"El-Kassas","year":"2023","journal-title":"Asian Pac J Cancer Prev"},{"issue":"11","key":"10.1016\/j.clinre.2025.102567_bib0027","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.4254\/wjh.v13.i11.1743","article-title":"Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: comparative analysis with antiviral therapy-naive patients","volume":"13","author":"Fouad","year":"2021","journal-title":"World J Hepatol"},{"key":"10.1016\/j.clinre.2025.102567_bib0028","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/JHC.S391511","article-title":"Changes in presentation, treatment, and survival of patients with hepatocellular carcinoma in Damietta, Egypt, 2007\u20132019: a retrospective monocentric cohort study","author":"Jean","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"issue":"3","key":"10.1016\/j.clinre.2025.102567_bib0029","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s12029-024-01076-w","article-title":"Impact of DAA treatment for HCV on hepatocellular carcinoma in a predominately African American population","volume":"55","author":"Itani","year":"2024","journal-title":"J Gastrointest Cancer"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125000476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125000476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T02:17:07Z","timestamp":1744510627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740125000476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2210740125000476"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102567","relation":{},"ISSN":["2210-7401"],"issn-type":[{"type":"print","value":"2210-7401"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in the presentation and characteristics OF HCV related hepatocellular carcinoma in the era of direct acting antiviral therapy: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102567","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102567"}}